| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 1st September 2020 | Lp Bleichroeder | 250,000 | Open or private sale | $1.68 | $420,000.00 |
| 21st August 2020 | Jon S Saxe | 30,000 | Open or private purchase | $0.69 | $20,700.00 |
| 3rd June 2020 | Judy R Joice | 34,864 | Exercise of derivative | $0.78 | $27,193.92 |
| 3rd June 2020 | Judy R Joice | 22,956 | Open or private sale | $2.45 | $56,283.52 |
| 3rd June 2020 | Judy R Joice | 22,956 | Exercise of derivative | $0.78 | $17,905.68 |
| 3rd June 2020 | Judy R Joice | 34,864 | Open or private sale | $2.45 | $85,479.56 |
| 26th May 2020 | Lp Bleichroeder | 39,388 | Open or private sale | $2.50 | $98,525.14 |
| 27th March 2020 | Lp Bleichroeder | 10,325 | Open or private sale | $4.09 | $42,199.31 |
| 26th March 2020 | Lp Bleichroeder | 17,175 | Open or private sale | $4.40 | $75,540.80 |
| 18th March 2020 | Lp Bleichroeder | 34,066 | Open or private purchase | $2.34 | $79,785.98 |
Durect
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.
DURECT Corp. engages in the research, development, and manufacturing of pharmaceutical products. The company products include alzet and lactel. Its pipeline includes DUR-928, which focuses on lipid homeostasis, inflammation, and cell survival; and POSIMIR, which is an analgesic product intended to deliver bupivacaine.
Ticker: DRRX
Sector: Health Technology
Industry: Pharmaceuticals: Major
SEC Central Index Key (CIK): 1082038
Employees: 90
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
There were no Red Flags found
Fundamentals
Cash at Carrying Value: $18 M (-47%)
Inventory, Net: $3 M (0%)
Assets, Current: $60 M (-16%)
Property, Plant and Equipment, Net: $476 Th (1%)
Other Assets, Noncurrent: $283 Th (-74%)
Assets: $73 M (-15%)
Accounts Payable, Current: $2 M (-4%)
Accrued Liabilities, Current: $4 M (-41%)
Liabilities, Current: $10 M (-71%)
Long-term Debt, Excluding Current Maturities: $21 M (0%)
Other Liabilities, Noncurrent: $891 Th (11%)
Common Stock, Value, Issued: $19 Th (0%)
Additional Paid in Capital, Common Stock: $521 M (1%)
Retained Earnings (Accumulated Deficit): $485 M (0%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $71 Th (2266%)
Stockholders' Equity (Parent): $36 M (0%)
Liabilities and Equity: $73 M (-15%)
Revenue: $26 M (0%)
Cost of Revenue: $964 Th (-56%)
Research and Development: $7 M (-53%)
Operating Income/Loss: $15 M (187%)
Other Income, net: $417 Th (-44%)
EPS (basic): $0.07 (0%)
EPS (diluted): $0.07 (0%)
